ABIVAX
€85.20Change from previous close: +1.25%Absolute change: +€1.05
Valuation
Data as of October 2, 2026
Valuation multiples
- Market cap
- €7.43B
- Enterprise value
- €6.32B
- Forward P/E
- -29.3
- Price/book
- 18.6
- Price/sales
- 1,591.9
- EV/EBITDA
- -21.7
- EV/revenue
- 1,352.9
Profitability and growth
- Gross margin
- 100.0%
- Operating margin
- -8,617.9%
- Net margin
- 0.0%
- ROE
- -252.3%
- ROA
- -62.9%
- Revenue growth (year over year)
- -6.8%
Financial health
- Total cash
- €402.38M
- Total debt
- €1.21M
- Debt/equity
- 0.00
- Current ratio
- 5.97
- Quick ratio
- 5.79
Dividends
- Payout ratio
- 0.0%
Analysts and estimates
- Average price target
- €135.01
- Median price target
- €132.00
- High price target
- €180.00
- Low price target
- €70.00
- Analysts with a price target
- 7
- Consensus
- Buy
- Forward EPS
- -€2.90
- EPS estimate, current year
- -€3.42
Shares and trading
- Beta
- -0.25
- Average volume
- 153.21K
- Shares outstanding
- 87.27M
- Float
- 69.03M
- Institutional ownership
- 50.3%
- Insider ownership
- 4.2%